Please login to the form below
BioNTech
This page shows the latest BioNTech news and features for those working in and with pharma, biotech and healthcare.
US FDA expands COVID-19 booster jabs to all adults
All Americans 18 and over are now eligible to receive a booster shot of either the Pfizer/BioNTech or Moderna COVID-19 vaccines. ... Now, all adults can receive a booster shot six months after a second dose of the Moderna or Pfizer/BioNTech vaccine or
Latest news
-
US government to pay $5.3bn for Pfizer‘s Paxlovid
Pfizer has also announced that it and BioNTech have received an expanded EUA for a booster dose of its vaccine, Comirnaty, for people aged 18 and over. ... US Food and Drug Administration (FDA) has expanded the EUA of a booster dose of the
-
AstraZeneca/Moderna’s mRNA treatment for heart failure looks promising
While mRNA technology has been in the headlines due to the Pfizer/BioNTech and Moderna COVID-19 vaccines, these results show that the approach has a wider potential.
-
UK expands COVID-19 vaccine plans as winter approaches
The UK government will offer a booster dose of an mRNA COVID-19 vaccine to all adults aged 40 and a second Pfizer/BioNTech shot for 16- and 17-year-olds. ... Now, all adults aged 40 and over can receive a booster dose of an mRNA vaccine – either
-
FDA opens door to COVID-19 booster jabs
The FDA has amended its emergency use authorisations for both approved mRNA vaccines – Pfizer/BioNTech’s Comirnaty and Moderna’s Spikevax – for use as a booster/third jab for “certain immunocompromised
-
Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
Pfizer has raised its financial guidance as its BioNTech-partnered COVID-19 vaccine continues to make gains, with the jab bringing in a total of $7.8bn in the second quarter ... Currently, Pfizer and BioNTech are expecting to manufacture up to three
More from news
Approximately 73 fully matching, plus 125 partially matching documents found.
Latest Intelligence
-
Rare genetic diseases – what’s in store for 2021?
So far the Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University vaccines have all received approval in the UK and other countries for the very disease that put all these changes into
-
Working together against COVID-19
Beyond the connection between HCPs and pharma or NGOs, it is encouraging to see collaborations such as Clover and GSK evaluating a vaccine candidate and Pfizer and Biontech doing the same.
-
COVID-19: the race to find a vaccine
BioNTech, CureVac and Translate Bio are also working on mRNA vaccines, while Pfizer and Sanofi are involved in those programmes through partnerships with BioNTech and Translate Bio, respectively.
-
Cancer immunotherapy: What's on the horizon?
Candidates from Neon Therapeutics, Aduro and BioNTech have passed early-stage testing and are now being studied along with checkpoint inhibitors to see if they can deliver a double-whammy to
-
Deal Watch September 2016
At a lower disclosed headline value of $310m BioNTech licensed its mRNA-based cancer vaccines platform to Genentech. ... The full value cannot be determined as BioNTech received the $310m in upfront and near-term milestone payments, no other financial
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
New hires at bluebird bio, BioNTech and Provention Bio
BioNTech. German biotech BioNTech has appointed Ryan Richardson(pictured below, right) as chief strategy officer and managing director. ... In his new role, he will support and contribute to the creation and implementation of BioNTech’s long-term growth
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest from PMHub
-
Genetic Digital
Proveca. Rosemont Pharma. Nemysis. Martindale Pharma. InHealth. BioNTech. Britannia Pharmaceuticals.
-
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
In the past year, we have seen partnerships between companies such as Pfizer and BioNTech; Oxford University and AstraZeneca and more recently GSK and CureVac.
-
What does the COVID-19 vaccine mean for the future of R&D?
Both the Oxford/AstraZeneca and Pfizer/BioNTech vaccines were developed using platform technologies which didn’t exist 20 years ago, allowing these vaccines to be developed much faster.
-
The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so
-
Mistrust in medical research: a patient perspective
Health Products Regulatory Agency’s speedy approval of the Pfizer-BioNTech COVID-19 vaccine in the UK. ... A good example is a recent incident in the UK that made headline news, where two NHS workers who were among the first to receive the
Genetic Digital
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- First trial of a vaccine against Alzheimer’s launches
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- AbbVie/Allergan merger faces renewed public opposition despite divestments
- AbbVie/Allergan's merger faces public opposition
- AstraZeneca officially opens new R&D facility in UK
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
